CLL
Conference Coverage
Three-drug combo promising against high-risk CLL
Conference Coverage
MCC response varies based on immunosuppression type, especially CLL
From the Journals
Race and location appear to play a role in the incidence of CLL and DLBCL
From the Journals
Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL
Interleukin-27 was able to increase cytotoxic effects of bone marrow natural killer cells in chronic lymphocytic leukemia (CLL).
News from the FDA/CDC
FDA approves ibrutinib-rituximab combo for newly diagnosed CLL, SLL in adults
Ibrutinib (Imbruvica) earns expanded indication for combination with rituximab as frontline treatment for adult CLL and SLL.
From the Journals
Five prognostic indexes come up short for planning early CLL treatment
From the Journals
One-third of high-risk CLL patients received treatment counter to recommendations
One-third of high-risk chronic lymphocytic leukemia patients received chemoimmunotherapy despite predicted poor outcomes.
From the Journals
Case study shows CLL may mask COVID-19 infection
COVID-19 was not initially suspected, as the patient’s whole blood cell and lymphocyte counts were high because of chronic lymphocytic leukemia....
Roundtables
CLL/SLL Roundtable: Updates On Patient Management
From the Journals
CLL and breast cancer differ in the expression of regulatory microRNAs
A particular microRNA was found to be associated with prevascular invasion.
From the Journals
NMA haploidentical allo-BMT plus post-transplant cyclophosphamide deemed safe, effective for CLL
Patients with less than 20% marrow CLL involvement before transplant had an improved 4 year survival.